Exagen (XGN) Expected to Announce Quarterly Earnings on Monday

Exagen (NASDAQ:XGN - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $14.55 million for the quarter.

Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The firm had revenue of $15.50 million for the quarter, compared to analysts' expectations of $14.55 million. During the same period last year, the firm earned ($0.19) earnings per share. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Trading Up 6.4 %

Shares of NASDAQ XGN traded up $0.41 during mid-day trading on Wednesday, hitting $6.83. The stock had a trading volume of 699,725 shares, compared to its average volume of 98,789. Exagen has a 1 year low of $1.35 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The business has a 50 day moving average price of $4.43 and a two-hundred day moving average price of $4.06. The firm has a market cap of $122.95 million, a P/E ratio of -7.27 and a beta of 1.50.

Analysts Set New Price Targets

XGN has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 target price on shares of Exagen in a research note on Monday, January 13th. William Blair reiterated an "outperform" rating on shares of Exagen in a report on Wednesday, March 12th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Exagen in a research report on Wednesday.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).